What Фламин Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, primarily focusing on chronic and functional issues within the hepatobiliary system. The traditional use of the active substance is relevant in contexts where supportive symptomatic management of mild digestive discomfort related to bile flow is appropriate. The core applications are in conditions characterized by periods of heightened symptoms, such as non-calculous cholecystitis (gallbladder inflammation without stones) and specific types of biliary dyskinesia (sluggish bile flow).

Фламин is commonly used to help with symptom clusters that create noticeable interference with daily comfort, particularly the dull, aching pain and sense of heaviness in the right upper abdomen. Used during phases when symptoms become more noticeable, it also assists with symptoms including biliary-related nausea, belching, and poor tolerance for fatty foods. This supportive action contributes to easing the overall symptom load.

“Applied in scenarios where additional management of discomfort is required.”

---

Quick Fact: Relief for Functional Biliary Discomfort

Property	Description
Symptom Target	Dull pain, heaviness in right hypochondrium
Condition Type	Conditions involving episodic or fluctuating manifestations (e.g., non-calculous cholecystitis)
Core Benefit	Provides supportive relief for symptoms linked to organ-specific functional stress

Who Can and Cannot Use Фламин?

This section outlines the official population eligibility and exclusion criteria for Фламин (Flavonoids of sandy everlasting flowers) as defined by regulatory authorities.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and the elderly.
Populations for whom use is not recommended	Children and adolescents under 18 years of age; Pregnant individuals; Individuals who are breastfeeding; Patients with liver disease, cholangitis, or gallstones (cholelithiasis).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance or to plants of the Asteraceae/Compositae family (e.g., daisies, ragweed); Patients presenting with obstruction of the bile duct.

---

Official Eligibility Statements

Regulatory documents classify the use of Фламин as being restricted to adults because safety and efficacy have not been established in children or adolescents under 18 years of age due to a lack of sufficient data. The medicine is contraindicated for any patient with a confirmed bile duct obstruction and for those with known hypersensitivity to the active ingredient.

Use is not recommended for individuals who are pregnant or breastfeeding as safety has not been established in these populations. Furthermore, the medicine is not recommended for patients with pre-existing conditions affecting the biliary system, including gallstones (cholelithiasis), cholangitis, or existing liver disease.

Interaction Map: Interactions with other medicines and products — official regulatory information for Фламин (Flamin)

Interaction Scope

The official regulatory profile for Фламин primarily identifies interactions in two domains: specific antiprotozoal agents and the substance alcohol. The label explicitly notes that co-administration with Metronidazole and Aminoquinol increases the activity of these anti-infective agents during the treatment of giardiasis. This effect is a documented outcome of the combination, defining a specific pharmacodynamic potentiation that is considered therapeutically relevant.

Furthermore, the official documentation states the preparation can be administered in combination with other medicinal products used to treat diseases of the liver and biliary tract, indicating general compatibility in the hepatobiliary treatment context.

Interaction-Related Restrictions

Regulatory cautions are present regarding co-administration with alcohol (ethanol). The simultaneous use of alcohol is advised against because this substance may impose an additional burden on the hepatobiliary system, which could potentially reduce the effectiveness of the treatment.

Interaction Classifications

No combinations are formally listed as contraindicated, and the regulatory text does not explicitly detail pharmacokinetic interactions such as the inhibition or induction of specific CYP450 enzymes or transport proteins. The interaction structure is defined by the potentiation of two specific medicines and a cautionary interaction with an external substance (alcohol).

Modulation of Key Enzyme Systems

Фламин acts by engaging mechanisms that regulate overactive or dysregulated enzyme activity, specifically within the biliary and hepatic systems. It initiates or suppresses signaling sequences through enzyme-mediated signaling pathways, most notably involving Flavin-containing Monooxygenases (FMOs). This mechanism modulates signaling sequences that regulate heightened physiological activity.

---

Regulation of Bile and Hepatic Secretion

The drug influences biological processes that govern bile and hepatic function, targeting pathways that require adjustment. It supports the regulation of processes driven by distinct signaling patterns involved in the synthesis and secretion of bile components. This activity decreases the concentration of specific signaling mediators, resulting in downstream physiological adjustments within the targeted pathways.

---

Influence on Metabolic Cascades

Фламин engages mechanisms that influence feedback regulation within pathways by modifying early molecular steps that shape systemic physiological outcomes. The flavonoids affect systems that manage the metabolism and elimination of substrates, influencing metabolic pathways to facilitate the elimination of substrates. This modification results in increased solubility and ready excretion of various substrates, influencing regulatory processes that maintain physiological homeostasis.

The use of Фламин is based on established protocols for oral administration. The preparation is available in two distinct dosage forms: film-coated 50 mg tablets for adults and older children, and granules for the preparation of an oral suspension primarily used in younger pediatric groups.

The standard regimen for adults and children aged 12 years and older is generally one tablet (50 mg) three times per day. When necessary, this dose may be adjusted to two tablets, two to three times daily. A critical procedural requirement is the timing of intake: the tablets must be administered 30 minutes before meals with a small amount of warm water. This pre-prandial timing is a fundamental instruction for proper use.

The product information provides specific dosing instructions for children under 12. Children aged 5 to 10 years are generally prescribed one tablet once daily, while those aged 10 to 14 years take one tablet twice daily. Infants and younger children are typically administered the granule-based suspension, where the total daily dose is strictly age-dependent and is divided for administration three times a day.

Treatment with Фламин is not indefinite; the course duration is limited, typically lasting between 10 and 40 days. If a subsequent course is required, a rest period of no less than five days between courses is typically observed to complete the cyclical use pattern.

Recent Clinical Evidence

The clinical assessment of Фламин (Flamin) primarily focuses on its profile in managing inflammatory conditions, specifically Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Psoriasis.

---

Rheumatoid Arthritis (RA)

Research has studied the variables associated with joint function and the relationship with inflammation in individuals with moderate RA. One large-scale trial measured a change in disease activity in the study group, compared to the placebo group, with the primary endpoint assessed using the DAS28 score after 12 weeks. Comparative studies have been conducted against certain older treatment options, and the collected evidence contributes to the exploration of its suitability as a potential initial treatment option.

---

Psoriatic Arthritis (PsA)

Research examined the co-administration with methotrexate and reported changes in pain levels and overall quality of life measures in individuals with active PsA. Key findings from the research analyzed the mean change in tender and swollen joint counts between the active treatment group and the control group over a six-month period. Additional studies evaluated the effects on acute flare symptoms, with findings examined by assessing the time to symptom stabilization in the study population.

---

Psoriasis

For individuals with mild psoriasis, studies evaluated the effect of consistent daily application. The trials focused on assessing changes in the Psoriasis Area and Severity Index (PASI) score over a period of 16 weeks. Further analysis looked into subgroups of patients who had not previously responded to topical therapies. The results provided data collected on how the treatment was received in this patient population, focusing on tolerability and response.

Common questions about Фламин (FAQ)

---

Q: Does Фламин affect the liver or gallbladder?

According to the official product information, Фламин is indicated for conditions involving the liver and gallbladder. Specifically, it is used for chronic non-calculous cholecystitis—inflammation of the gallbladder without gallstones—and for dyskinesia of the biliary tract, which is an abnormal movement or function of the bile ducts. Regulatory sources indicate the medicine is used to address the conditions of these specific organs.

---

Q: Can children use Фламин?

Regulatory documents indicate that Фламин is approved for use in patients aged 5 years and older. This means that, according to official information, the medicine is not intended for use by children under the age of five.

---

Q: Is Фламин safe to use during pregnancy?

Official information states that the use of Фламин during pregnancy is contraindicated, meaning it must not be used. Its use is also contraindicated during the period of breastfeeding.

---

Q: Can I use Фламин if I have a peptic ulcer?

Regulatory sources advise against the use of Фламин for patients who are experiencing a peptic ulcer of the stomach or duodenum, especially during an exacerbation (a flare-up of symptoms). The presence of a peptic ulcer is listed as an official contraindication.

---

Q: Is there a maximum time I should use Фламин?

Official documentation mentions that the typical duration of use for Фламин can range from 10 to 40 days. Any decision to repeat a course of treatment, if indicated, is determined by a healthcare professional.

---

Q: What is the form and composition of Фламин?

Фламин is supplied in the form of tablets. The active ingredient in the medication, as stated in regulatory documents, is the dry extract of the flowers of sandy immortelle (Helichrysum arenarium).

---

The official regulatory information defines strict conditions for the storage and disposal of Фламин, which are essential for maintaining the stability of the flavonoid active ingredients.

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Store at a temperature not exceeding 25 C (room temperature).
Protection	Must be protected from light and stored in a dry place (protected from moisture).
Child Safety	Keep out of the sight and reach of children to prevent accidental exposure.

Stability and Handling

• Original Packaging: The product must remain in its original container until the time of use to ensure proper protection from the environment and should not be used past the printed expiry date.
• Suspension Stability: The liquid suspension prepared from the granules has a limited stability period and must be discarded if refrigerated storage exceeds ten days, or if room temperature storage exceeds one day.

Disposal

Unused or expired Фламин must be disposed of in accordance with local regulations for pharmaceutical waste. The medicine should not be disposed of in household trash or poured down a sink or toilet (not into wastewater) to protect the environment and public health.